Claim being checked · Version 1 · Reviewed
“Cerebrolysin has been studied in randomized human trials.”
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
No dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Supported with scope. The reviewed evidence supports this exact statement only in the situation described below.
Answer scope
This verdict checks the exact claim in the heading. It is not a universal grade for Cerebrolysin.
01 · Answer
Supported with scope
Yes. CASTA and other randomized studies tested the named product in defined groups and settings. The existence of these studies does not prove a benefit for every outcome or product.
- What kind of evidence this is
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- What this answer covers
- The exact Cerebrolysin product, study group, comparison, outcome, and follow-up period in each randomized trial. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
- Question type
- Clinical outcomes. What a study measured about people's health, symptoms, or ability to function.
02 · Sources
Read the sources behind this answer
01CASTA randomized acute stroke trialPubMed · Stroke · Randomized trial · 2012
Supports the scoped claim02Cochrane review of Cerebrolysin for acute ischemic strokePubMed · Cochrane Database of Systematic Reviews · Science review · 2023
Supports the scoped claim03Cochrane review of Cerebrolysin for vascular dementiaPubMed · Cochrane Database of Systematic Reviews · Science review · 2019
Supports the scoped claim
Supports the scoped claim02Cochrane review of Cerebrolysin for acute ischemic strokePubMed · Cochrane Database of Systematic Reviews · Science review · 2023
Supports the scoped claim03Cochrane review of Cerebrolysin for vascular dementiaPubMed · Cochrane Database of Systematic Reviews · Science review · 2019
Supports the scoped claim
- Editorial review
- Internal editorial review recorded
- Source review
- Anthony Treviso · Founder and responsible editor
- Medical review status
- Not independently medically reviewed. Editorial source review does not replace medical review.